Revision 4

store at -20C	EWS Antibody		<b>Cell Signaling</b> TECHNOLOGY®
		Orders:	877-616-CELL (2355) orders@cellsignal.com
0		Support	: 877-678-TECH (8324)
191		Web:	info@cellsignal.com cellsignal.com
#1	31	Trask Lane   Danvers   I	Massachusetts   01923   USA

For Research Use Only.	Not for Use in	Diagnostic	Procedures.
------------------------	----------------	------------	-------------

Applications: W, IP	Reactivity: H M R	<b>Sensitivity:</b> Endogenous	<b>MW (kDa):</b> 85	Source/Isotype: Rabbit	<b>UniProt ID:</b> #Q01844	Entrez-Gene Id: 2130
Product Usage Information		<b>Application</b> Western Blotting Immunoprecipitation		5) 150 mM NoCl 100 up	<b>Dilution</b> 1:1000 1:50	reard Store at
Storage		20°C. Do not aliquot th	ie antibody.	s), 150 mm NaCi, 100 μg.	mi BSA and 50% gi	/Cerol. Store at –
Specificity/Sen	sitivity	EWS Antibody recogniz	zes endogenous le	vels of total EWS protein		
Source / Purific	cation	Polyclonal antibodies a residues surrounding ( affinity chromatograph	are produced by im Gly142 of human E าy.	munizing animals with WS protein. Antibodies a	a synthetic peptide are purified by prote	corresponding to ein A and peptide
Background		The Ewing sarcoma (EV of proteins (1,2). These for both transcriptiona with various E-twenty s family of tumors (1-4). domain, is fused to the expression of target ge RNA polymerase II sub suggests a role for EW components of the spli regulates the expressio level of transcriptional promote the expressio regulates the DNA dam response and is require knockout mice display suggesting a role for E	VS) protein is a me proteins are RNA I regulation and R six (ETS) family trar The amino termin e DNA binding don enes (1-5). EWS inte ounits, as well as tr S in transcriptiona icing machinery, ir on of cyclin D1, wh activation and mR n of the cyclin D1b nage-induced alter ed for cell viability hypersensitivity to WS in homologous	mber of the multifunction and DNA binding protein NA processing. EWS can ascription factors, most us of the EWS protein, con- tain of the ETS transcrip eracts with the transcrip anscriptional regulators. I regulation (1,6-9). EWS inplicating a role for EWS ich controls G1-S phase NA splicing. The EWS-Flip on splice variant in Ewing native splicing of genes upon DNA damage (14). to ionizing radiation and pa- s recombination and ma-	onal FET (FUS, EWS, ns that are thought be found as part of commonly Fli-1, in ti ontaining the transc tion factor, causing such as Brn3A and also interacts with r in RNA processing transition during th -1 fusion protein ha sarcoma cells (13). I involved in DNA rep Consistent with the oremature cellular s intenance of genor	and TAF15) family to be important a fusion protein he Ewing sarcoma riptional activation aberrant lex via TFIID and CBP/p300, which nultiple (1,10-12). EWS e cell cycle, at the s been shown to n addition, EWS pair and stress ese results, EWS enescence, nic stability (15).
Background Re	eferences	1. Law, W.J. et al. (2006, 2. Kovar, H. (2011) <i>Sarc</i> 3. Delattre, O. et al. (199 4. May, W.A. et al. (1995 5. Sorensen, P.H. et al. ( 6. Bertolotti, A. et al. (1 7. Bertolotti, A. et al. (1 8. Araya, N. et al. (2003 9. Thomas, G.R. and La 10. Chansky, H.A. et al. 11. Yang, L. et al. (2000 12. Knoop, L.L. and Bal 13. Sanchez, G. et al. (2 14. Paronetto, M.P. et a 15. Li, H. et al. (2007) <i>J</i>	) Brief Funct Geno, oma 2011, 837474 (92) Nature 359, 16 3) Mol Cell Biol 13, (1994) Nat Genet ( 996) EMBO J 15, 50 998) Mol Cell Biol (9) J Biol Chem 278, (1001) Cancer Res (2001) J Biol (2001) J Biol (2001) J Biol (2011) Mol Cell 4 Clin Invest 117, 13	<i>mic Proteomic</i> 5, 8-14. 52-5. 7393-8. 5, 146-51. 522-31. 18, 1489-97. 5427-32. <i>er Biol Ther</i> 1, 428-32. 61, 3586-90. 37612-8. <i>I Chem</i> 276, 22317-22. <i>od Sci U S A</i> 105, 6004-9. 13, 353-68. 14-23.		
Species Poactin	vity	Species reactivity is det	termined by testin	a in at least one approve	ad application (o.g.	western blot)
species Reactiv	vity	species reactivity is del	termined by testin	y in at least one approve	application (e.g.,	
Western Blot B	Buffer	IMPORTANT: For weste TBS, 0.1% Tween® 20 a	ern blots, incubate at 4°C with gentle s	membrane with diluted shaking, overnight.	primary antibody ir	1 5% w/v BSA, 1X

Applications Key	W: Western Blotting IP: Immunoprecipitation
Cross-Reactivity Key	H: Human M: Mouse R: Rat
Trademarks and Patents	Cell Signaling Technology is a trademark of Cell Signaling Technology, Inc.
	All other trademarks are the property of their respective owners. Visit cellsignal.com/trademarks for more information.
Limited Uses	Except as otherwise expressly agreed in a writing signed by a legally authorized representative of CST, the following terms apply to Products provided by CST, its affiliates or its distributors. Any Customer's terms and conditions that are in addition to, or different from, those contained herein, unless separately accepted in writing by a legally authorized representative of CST, are rejected and are of no force or effect.
	Products are labeled with For Research Use Only or a similar labeling statement and have not been approved, cleared, or licensed by the FDA or other regulatory foreign or domestic entity, for any purpose. Customer shall not use any Product for any diagnostic or therapeutic purpose, or otherwise in any manner that conflicts with its labeling statement. Products sold or licensed by CST are provided for Customer as the end-user and solely for research and development uses. Any use of Product for diagnostic, prophylactic or therapeutic purposes, or any purchase of Product for resale (alone or as a component) or other commercial purpose, requires a separate license from CST. Customer shall (a) not sell, license, loan, donate or otherwise transfer or make available any Product to any third party, whether alone or in combination with other materials, or use the Products to manufacture any commercial products, (b) not copy, modify, reverse engineer, decompile, disassemble or otherwise attempt to discover the underlying structure or technology of the Products, or use the Products for the purpose of developing any products or services that would compete with CST products or services, (c) not alter or remove from the Products solely in accordance with CST Product Terms of Sale and any applicable documentation, and (e) comply with any license, terms of service or similar agreement with respect to any third party products or services used by Customer in connection with the Products.